@article{fdi:010052984,
  title = {{A}ntiretroviral drug resistance mutations in antiretroviral-naive patients from {S}enegal},
  author = {{D}iop-{N}diaye, {H}. and {T}oure-{K}ane, {C}. and {L}eye, {N}. and {N}gom-{G}ueye, {N}. {F}. and {M}ontavon, {C}{\'e}line and {P}eeters, {M}artine and {M}boup, {S}.},
  editor = {},
  language = {{ENG}},
  abstract = {{T}o evaluate the presence of drug resistance mutations in antiretroviral-naive patients in {D}akar ({S}enegal), cross-sectional studies were conducted since the circulation of {ARV}s in the country. {P}rotease and {RT} genes were sequenced in 96 baseline samples from patients included in the {S}enegalese {I}nitiative for {A}ntitretroviral {A}ccess treatment between 1998 and 2001 and for 104 samples from naive, recently diagnosed patients in 2003, 2005, and 2007. {P}hylogenetic analysis showed a predominance of {CRF}02_{AG} [128/200 (64%)] and a high genetic diversity with 10 other variants and 25 {URF}s. {A}nalysis for the presence of drug resistance mutations according to the {WHO} {SDRM} 2009 list showed a prevalence of 4.16% for nucleoside inhibitors and 1.04% for protease inhibitors at the start of the structured {S}enegalese {ART} initiative and 1.9% for protease inhibitors at the time of scaling up. {T}he prevalence in untreated patients remains low and stable, below 5% after 10 years of {ARV} circulation.},
  keywords = {},
  booktitle = {},
  journal = {{A}ids {R}esearch and {H}uman {R}etroviruses},
  volume = {26},
  numero = {10},
  pages = {1133--1138},
  ISSN = {0889-2229},
  year = {2010},
  DOI = {10.1089/aid.2009.0295},
  URL = {https://www.documentation.ird.fr/hor/fdi:010052984},
}